Liquidia Corporation

NasdaqCM LQDA

Liquidia Corporation Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.21

Liquidia Corporation Revenue Per Share is USD 0.21 for the Trailing 12 Months (TTM) ending September 30, 2024, a -25.37% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Liquidia Corporation Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.28, a 18.28% change year over year.
Liquidia Corporation Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.24, a 7.92% change year over year.
Liquidia Corporation Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.22.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqCM: LQDA

Liquidia Corporation

CEO	Dr. Roger A. Jeffs Ph.D.
IPO Date	July 26, 2018
Location	United States
Headquarters	419 Davis Drive
Employees	145
Sector	Health Care
Industries Pharmaceuticals

Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Key trends

Past 5 years